Tetramethylpyrazine Nitrone (TBN) Reduces Amyloid β Deposition in Alzheimer's Disease Models by Modulating APP Expression, BACE1 Activity, and Autophagy Pathways

被引:0
|
作者
Zhou, Xinhua [1 ]
Zhu, Zeyu [2 ]
Kuang, Shaoming [1 ]
Huang, Kaipeng [1 ]
Li, Yueping [1 ]
Wang, Yuqiang [2 ,3 ,4 ]
Chen, Haiyun [5 ]
Hoi, Maggie Pui Man [6 ]
Xu, Benhong [7 ]
Yang, Xifei [7 ]
Zhang, Zaijun [2 ,3 ,4 ]
机构
[1] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou Med Res Inst Infect Dis, Guangzhou 510440, Peoples R China
[2] Jinan Univ, Inst New Drug Res, State Key Lab Bioact Mol & Druggabil Assessment, Guangzhou Key Lab Innovat Chem Drug Res Cardiocere, Guangzhou 511436, Peoples R China
[3] Jinan Univ, Coll Pharm, Guangdong Hong Kong Macau Joint Lab Pharmacodynam, Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou 511436, Peoples R China
[4] Jinan Univ, Coll Pharm, Chinese Minist Educ MOE, Int Cooperat Lab Tradit Chinese Med Modernizat & I, Guangzhou 511436, Peoples R China
[5] Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Peoples R China
[6] Univ Macau, Inst Chinse Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China
[7] Shenzhen Ctr Dis Control & Prevent, Key Lab Modern Toxicol Shenzhen, Shenzhen 518055, Peoples R China
基金
中国国家自然科学基金;
关键词
amyloid beta; amyloid precursor protein; microRNA; PROTEIN;
D O I
10.3390/ph17081005
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alzheimer's disease (AD) is a neurodegenerative disorder associated with age. A wealth of evidence indicates that the amyloid beta (A beta) aggregates result from dyshomeostasis between A beta production and clearance, which plays a pivotal role in the pathogenesis of AD. Consequently, therapies targeting A beta reduction represent a promising strategy for AD intervention. Tetramethylpyrazine nitrone (TBN) is a novel tetramethylpyrazine derivative with potential for the treatment of AD. Previously, we demonstrated that TBN markedly enhanced cognitive functions and decreased the levels of A beta, APP, BACE 1, and hyperphosphorylated tau in 3xTg-AD mice. However, the mechanism by which TBN inhibits A beta deposition is still unclear. In this study, we employed APP/PS1 mice treated with TBN (60 mg/kg, ig, bid) for six months, and N2a/APP695swe cells treated with TBN (300 mu M) to explore the mechanism of TBN in A beta reduction. Our results indicate that TBN significantly alleviated cognitive impairment and reduced A beta deposition in APP/PS1 mice. Further investigation of the underlying mechanisms revealed that TBN decreased the expression of APP and BACE1, activated the AMPK/mTOR/ULK1 autophagy pathway, inhibited the PI3K/AKT/mTOR/ULK1 autophagy pathway, and decreased the phosphorylation levels of JNK and ERK in APP/PS1 mice. Moreover, TBN was found to significantly reduce the mRNA levels of APP and BACE1, as well as those of SP1, CTCF, TGF-beta, and NF-kappa B, transcription factors involved in regulating gene expression. Additionally, TBN was observed to decrease the level of miR-346 and increase the levels of miR-147 and miR-106a in the N2a/APP695swe cells. These findings indicate that TBN may reduce A beta levels likely by reducing APP expression by regulating APP gene transcriptional factors and miRNAs, reducing BACE1 expression, and promoting autophagy activities.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] MiR-340 Reduces the Accumulation of Amyloid-β Through Targeting BACE1 (β-site Amyloid Precursor Protein Cleaving Enzyme 1) in Alzheimer's Disease
    Tan, Xianpei
    Luo, Yi
    Pi, Dingfang
    Xia, Liexin
    Li, Zhilian
    Tu, Qiang
    CURRENT NEUROVASCULAR RESEARCH, 2020, 17 (01) : 86 - 92
  • [42] QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer's Disease
    Ponzoni, Ignacio
    Sebastian-Perez, Victor
    Martinez, Maria J.
    Roca, Carlos
    De la Cruz Perez, Carlos
    Cravero, Fiorella
    Vazquez, Gustavo E.
    Paez, Juan A.
    Diaz, Monica F.
    Campillo, Nuria E.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [43] QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer’s Disease
    Ignacio Ponzoni
    Víctor Sebastián-Pérez
    María J. Martínez
    Carlos Roca
    Carlos De la Cruz Pérez
    Fiorella Cravero
    Gustavo E. Vazquez
    Juan A. Páez
    Mónica F. Díaz
    Nuria E. Campillo
    Scientific Reports, 9
  • [44] miR-15b represses BACE1 expression in sporadic Alzheimer's disease
    Gong, Guohua
    An, Fengmao
    Wang, Yu
    Bian, Ming
    Yu, Li-Jun
    Wei, Chengxi
    ONCOTARGET, 2017, 8 (53) : 91551 - 91557
  • [45] Promoter Polymorphisms Which Modulate BACE1 Expression Are Associated With Sporadic Alzheimer's Disease
    Wang, Shan
    Jia, Jianping
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2010, 153B (01) : 159 - 166
  • [46] Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice
    Li, Song
    Hou, Huayan
    Mori, Takashi
    Sawmiller, Darrell
    Smith, Adam
    Tian, Jun
    Wang, Yanjiang
    Giunta, Brian
    Sanberg, Paul R.
    Zhang, Sheqing
    Tan, Jun
    SCIENTIFIC REPORTS, 2015, 5
  • [47] Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer’s mice
    Song Li
    Huayan Hou
    Takashi Mori
    Darrell Sawmiller
    Adam Smith
    Jun Tian
    Yanjiang Wang
    Brian Giunta
    Paul R. Sanberg
    Sheqing Zhang
    Jun Tan
    Scientific Reports, 5
  • [48] BACE1 SUMOylation increases its stability and escalates the protease activity in Alzheimer's disease
    Bao, Jian
    Qin, Min
    Mahaman, Yacoubou Abdoul Razak
    Zhang, Bin
    Huang, Fang
    Zeng, Kuan
    Xia, Yiyuan
    Ke, Dan
    Wang, Qun
    Liu, Rong
    Wang, Jian-Zhi
    Ye, Keqiang
    Wang, Xiaochuan
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (15) : 3954 - 3959
  • [49] Cerebrospinal Fluid BACE1 Activity and sAβPPβ as Biomarker Candidates of Alzheimer's Disease
    Alexopoulos, Panagiotis
    Thierjung, Nathalie
    Grimmer, Timo
    Ortner, Marion
    Economou, Polychronis
    Assimakopoulos, Konstantinos
    Gourzis, Philippos
    Politis, Antonios
    Perneczky, Robert
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2018, 45 (3-4) : 152 - 161
  • [50] BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer’s disease
    Linda Chami
    Frédéric Checler
    Molecular Neurodegeneration, 7